Skip to content 
AMM 229: Evolus Study Unveils Millennial Botox Triumph
October 11, 2024
This episode delves into a new study revealing that prabotulinumtoxinA, a type of Botox, is particularly effective among millennials. Dr. Rui Avelar, head of research and development at Evolus, shares insights from a post hoc analysis of 737 adults treated for glabellar lines. While over 90% of nonmillennials responded well, 100% of millennials saw positive results, with satisfaction rates exceeding 98% at various checkpoints. The episode explores why millennials may experience higher effectiveness and satisfaction, attributing it to their proactive approach to anti-aging and the mood-enhancing benefits of the treatment.
Quick Takes
- A new study on prabotulinumtoxinA shows higher effectiveness among millennials
- 100% of millennials experienced positive results compared to over 90% of nonmillennials
- High satisfaction levels among millennials at days 7, 14, and 30 post-treatment
Episode Transcript
Today is October 11, 2024, and a new study reveals fascinating insights into the effectiveness of prabotulinumtoxinA, a type of Botox, especially among millennials. Led by Dr. Rui Avelar, head of research and development and chief medical officer at Evolus, the post hoc analysis examined 737 adults receiving this treatment for glabellar lines.
Notably, while over 90% of nonmillennials responded well, a perfect 100% of millennials saw positive results. Satisfaction levels among millennials soared with more than 98% expressing satisfaction at days 7, 14, and 30 post-treatment, compared to over 85% of nonmillennials.
Dr. Avelar’s findings suggest that neurotoxin injections are more effective and satisfying for millennials, potentially due to their proactive approach to anti-aging and the mood-enhancing benefits of the treatment.
